Prof. Lin Shen
✓ Available through China Expert Care
Director, Department of Gastrointestinal Oncology, and Director, Phase I Clinical Trial Ward; Professor and Chief Physician
Department of Gastrointestinal Oncology, Peking University Cancer Hospital

Focus: Drug treatment of stomach and other gastrointestinal cancers, including immunotherapy and CLDN18.2 CAR-T therapy
Prof. Shen leads the Department of Gastrointestinal Oncology at Peking University Cancer Hospital. Senior author of the pivotal randomised trial of satri-cel, the first randomised CAR-T trial in a solid tumour, on which its 2026 approval in China was based, and first author of the phase III trial of cadonilimab plus chemotherapy as first-line treatment for advanced stomach cancer.
Conditions: Stomach cancer, CAR-T cell therapy
Selected publications
- Lancet, 2025 (senior author): Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. PubMed 40460847
- Nature Medicine, 2025 (first author): First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. PubMed 39843940
- Nature Medicine, 2024 (senior author): Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. PubMed 38830992
- Lancet Oncology, 2013 (first author): Management of gastric cancer in Asia: resource-stratified guidelines. PubMed 24176572
Profile on the hospital website: https://www.bjcancer.org/Html/Doctors/Main/Index_31049.html
Request a written opinion from Prof. Lin Shen
Send your records. A medical coordinator will reply within 24 hours.
Start here